Neurological syndromes associated with MOG- and AQP4-antibodies now appear as two separate demyelinating diseases, characterized by distinct pathophysiology: AQP4-NMOSD is an astrocytopathy while MOGAD currently appears as an oligodendrogliopathy [18]. This evidence concerns the gene MOG and demyelinating disease.